In a study of IL-6R inhibitors (tocilizumab and sarilumab) from the FAERS database, there was a strong correlation with gastrointestinal issues, except for hypercholesterolemia, severe infections, diabetes, and nervous system disorders [24]. The gene discussed is IL6R; the disease is Hypercholesterolemia.